Moderna norovirus vaccine trial on hold by US FDA over neurological side effect
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Moderna to Present at Upcoming Conferences in March 2025
Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: ...
Moderna Stock Falls on Earnings Report. The Results Reaffirm a Grim Picture for Vaccine Maker.
Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...
Moderna’s Shot Sales, Canceled Contract Lead to Another Loss
Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for a canceled ...
Moderna beats on revenue but loses more than expected as it scales down manufacturing
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
Moderna Posts Wider-Than-Expected Q4 Loss, 2025 Sales Outlook Disappoints
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 12.2% in the fourth quarter, Holdings Channel reports. The firm owned 15,368 shares of ...
Moderna's Q4 Loss Wider Than Expected
The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...
Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
Moderna Scales Down Manufacturing
The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.